Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $133K | $2.61M | $51.5M | $104M | $271M | $351M | $363M | $434M | $560M | $673M |
| Revenue growth | — | 1863.9% | 1871.5% | 101.4% | 161.3% | 29.7% | 3.4% | 19.5% | 29.0% | 20.2% |
| Operating income | -$248M | -$329M | -$371M | -$424M | -$330M | -$382M | -$649M | -$569M | -$536M | -$535M |
| Operating margin | -186471.4% | -12593.5% | -721.2% | -409.0% | -121.8% | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% |
| Net income | -$246M | -$302M | -$198M | -$403M | -$187M | -$454M | -$707M | -$607M | -$569M | -$575M |
| Net margin | -184867.7% | -11567.3% | -383.7% | -388.3% | -68.8% | -129.2% | -194.7% | -139.9% | -101.6% | -85.4% |
| EPS (diluted) | -$6.21 | -$7.12 | -$3.97 | -$7.12 | -$3.07 | -$6.70 | -$10.12 | -$8.25 | -$6.29 | -$5.83 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$161M | -$254M | -$291M | -$345M | -$132M | -$339M | -$380M | -$475M | -$414M | -$466M |
| Capital expenditures | $10.2M | $2.79M | $4.08M | $24.8M | $43.9M | $73.1M | $116M | $44.0M | $7.00M | $6.00M |
| Free cash flow | -$171M | -$257M | -$295M | -$370M | -$176M | -$412M | -$497M | -$519M | -$421M | -$472M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $161M | $100M | $113M | $434M | $714M | $308M | $133M | $214M | $174M | $421M |
| Total assets | $541M | $491M | $720M | $1.14B | $1.76B | $1.52B | $1.55B | $1.49B | $1.50B | $1.53B |
| Total liabilities | $66.7M | $107M | $111M | $482M | $605M | $600M | $1.19B | $1.22B | $1.24B | $1.60B |
| Shareholders' equity | $474M | $383M | $609M | $654M | $1.15B | $923M | $352M | $275M | $255M | -$80.0M |
| Retained earnings | -$531M | -$833M | -$1.03B | -$1.43B | -$1.62B | -$2.07B | -$2.78B | -$3.39B | -$3.96B | -$4.53B |
| Shares (wtd avg diluted) | 41.2M | 44.2M | 50.9M | 57.8M | 60.8M | 67.8M | 69.9M | 73.5M | 90.5M | 98.6M |
Every figure is extracted from Ultragenyx Pharmaceutical Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.